Increased circulating levels of SP-D and IL-10 are associated with the development of disease severity and pulmonary fibrosis in patients with COVID-19

Frontiers in Immunology, Journal Year: 2025, Volume and Issue: 16

Published: March 14, 2025

Patients with severe COVID-19 can rapidly develop acute respiratory distress syndrome (ARDS), which further increases the risk of developing pulmonary fibrosis. The exact role macrophage polarization and different cytokine production in pathophysiology associated induced ARDS or fibrosis is unknown. It necessary to identify potential biomarkers that predict progress other adverse consequences. We analyze plasma samples obtained from healthy individuals patients who were stratified according disease severity fibrotic-like changes on chest computed tomography (CT) scans. Surfactant Protein D (SP-D), Matrix Metalloproteinase 8 (MMP8), Krebs von den lungen-6 (KL-6), Angiotensin-Converting Enzyme 2 (ACE2), polarization-related determined by ELISA. Data collected evaluated using regression models receiver operating characteristic (ROC) curves. levels SP-D, MMP8 higher than those non-ARDS patients. had SP-D compared without fibrotic changes. Among indicative polarization, patients, a significant increase IL-10, Inducible nitric oxide synthase (iNOS), Arginase-1 (Arg-1) observed while Tumor necrosis factor-α (TNF-α) was decreased. level IL-10 also elevated CT, positively correlated ACE2 Arg-1. ROC curve results uncovered showed efficacy predicting inflammatory markers. And similar predictive value traditional indicators such as CRP PCT. exhibited certain abilities for development COVID-19. determination these cytokines upon admission crucial evaluating prognosis

Language: Английский

Prediction Value of KREBS Von Den Lungen-6 (KL-6) Biomarker in COVID-19 Patients: A Systematic Review and Meta-Analysis

Journal of Clinical Medicine, Journal Year: 2022, Volume and Issue: 11(21), P. 6600 - 6600

Published: Nov. 7, 2022

The SARS-CoV-2 (COVID-19) pandemic is a major issue that necessitates the use of cutting-edge disease prediction models. aim study was to assess existing evidence regarding association between Krebs von den Lungen-6 levels and COVID-19 severity. A literature search performed on Web Science, PubMed, Scopus Cochrane Central Register Controlled Trials databases from 1 January 2020 up 2 August 2022. electronic database supplemented by searching Google Scholar. In addition, reference lists relative articles were also reviewed. KL-6 among positive vs. negative patients varied amounted 443.37 ± 249.33 205.73 86.8 U/mL (MD = 275.33; 95%CI: 144.57 406.09; p < 0.001). level 402.82 261.16 in severe group statistically significantly higher than non-severe (297.38 90.46 U/mL; MD 192.45; 118.19 266.72; mild 272.28 95.42 U/mL, compared 268.04 55.04 moderate −12.58; −21.59 −3.57; 0.006). Our meta-analysis indicates significant increased infection. Moreover, are with more course COVID-19, indicating may be useful predictor identify at risk for COVID-19.

Language: Английский

Serum Krebs von den Lungen-6 for Predicting the Severity of COVID-19: A Systematic Review, Meta-Analysis, and Trial Sequence Analysis

Clinical Medicine Insights Circulatory Respiratory and Pulmonary Medicine, Journal Year: 2023, Volume and Issue: 17

Published: Jan. 1, 2023

This systematic review and meta-analysis aimed to find the association between serum Krebs von den Lungen-6 (KL-6) severity of Coronavirus disease 2019 (COVID-19) infection.Databases Embase, PubMed, Web Science, Science Direct, Google Scholar were searched for studies reporting KL-6 levels in COVID-19 patients, published January 2020 September 30 2022.For comparison groups, standard mean difference (SMD) 95% confidence intervals (CI) computed as effect sizes. Sensitivity, specificity, positive likelihood ratio (PLR), negative (NLR) measured assess diagnostic power KL-6. In addition, summary receiver operating characteristics curve (sROC) was constructed summarize true (TP), false (FP) rates. To validate findings meta-analysis, Trial Sequential Analysis (TSA) conducted.Altogether 497 severe patients 934 non-severe (mild moderate) included. Pooling 12 indicated that level had significant with infection: = 1.18 (95% CI: 0.93-1.43), p 0.01; I2: 58.56%]. Pooled parameters calculated from eight were: sensitivity 0.53 0.47-0.59); specificity 0.90 0.88-0.93); 4.80 3.53-6.53); 0.46 0.32-0.68); area under curve: 0.8841. Additionally, TSA verified adequacy sample size robustness meta-analysis.Serum has a moderate degree correlation infection but low sensitivity. So, it is not recommended screening test infection.

Language: Английский